On Thursday, Shares of Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW), gained 11.58% to $48.74, hitting its highest level.
Atlas Air Worldwide, declared adjusted net income attributable to common stockholders of $25.7 million, or $1.03 per diluted share, for the three months ended March 31, 2015, contrast with $11.3 million, or $0.45 per diluted share, for the three months ended March 31, 2014.
On a stated basis, net income attributable to common stockholders in the first quarter of 2015 totaled $29.2 million, or $1.17 per diluted share, contrast with $7.9 million, or $0.32 per diluted share, in the year-ago quarter.
Free cash flow of $80.2 million in the first quarter contrast with $36.9 million in the first quarter of 2014.
Atlas Air Worldwide Holdings, Inc., through its auxiliaries, provides outsourced aircraft and aviation operating services worldwide. It operates through ACMI, Charter, and Dry Leasing segments.
At the end of Thursday’s trade, Shares of Tetra Tech Inc. (NASDAQ:TTEK), jumped 11.43% to $27.11.
Tetra Tech, declared that Company executives will deliver presentations to investors at the following investor conferences in May:
Baird Growth Stock Conference, Chicago, IL
Wednesday, May 6, 2015 at 3:00 p.m. Central Time, Presenter: Dan Batrack, Chairman and Chief Executive Officer.
Tetra Tech, Inc., together with its auxiliaries, provides consulting, engineering, program administration, construction administration, and technical services for water, environment, energy, infrastructure, and natural resources sectors.
Ferro Corporation (NYSE:FOE), ended its last trade with 10.94% gain, and closed at $13.49.
Ferro Corporation, stated results for the first quarter ended March 31, 2015. First quarter income from ongoing operations attributable to common shareholders was $0.17 per diluted share contrast with $0.12 per diluted share in the first quarter of 2014. On an adjusted basis, earnings per diluted share were $0.23 contrast with earnings of $0.14 per diluted share in the first quarter of 2014. The results in both years comprise a number of charges relating to, among other items, restructuring activities, and the impact of currency devaluations in Venezuela. Please refer to the supplemental tables at the end of this release for additional information concerning adjusted financial results.
First quarter 2015 net sales were $263 million, while value-added sales, which exclude precious metal sales, were $253 million. In the same period last year, net sales and value-added sales were $281 million and $267 million, respectively. On a constant currency basis, value-added sales raised 7%, with foreign currency translation adversely impacting value-added sales by about $31 million.
The Company attributed the enhance in adjusted earnings to improved profitability in the Performance Colors and Glass and Pigments, Powders and Oxides (“PPO”) segments, on a constant currency basis, coupled with reduced selling, general and administrative (“SG&A”) expenses and a lower effective tax rate, partially offset by unfavorable currency translation impacts.
Ferro Corporation, together with its auxiliaries, produces specialty materials in the United States and internationally. It operates through four business units: Tile Coating Systems; Porcelain Enamel; Performance Colors and Glass; and Pigments, Powders and Oxides.
Finally, AtriCure, Inc. (NASDAQ:ATRC), closed at $22.01, with 10.27% gain, hitting its highest level.
AtriCure, declared first quarter 2015 financial results.
First Quarter 2015 Financial Results
Revenue for the first quarter of 2015 was $29.9 million, an enhance of $5.0 million or 20.3% (24.0% on a constant currency basis), contrast to first quarter 2014 revenue. Domestic revenue raised 26.3% to $22.9 million, driven by strong sales of ablation-related open-heart products, ablation-related minimally invasive products, and AtriClip products. International revenue was $7.0 million, an enhance of $0.3 million or 3.9% (17.6% on a constant currency basis) contrast to $6.7 million for the first quarter of 2014. International revenue growth was driven primarily by enhances in product sales in Europe.
Gross profit for the first quarter of 2015 was $21.7 million contrast to $17.7 million for the first quarter of 2014. Gross margin for the first quarter of 2015 and 2014 was 72.7% and 71.1%, respectively. The enhance in gross margin was primarily due to the heavier U.S. sales mix, favorable product costs and the elimination of certain acquisition transition costs comprised of in the three months ended March 31, 2014.
Operating expenses for the first quarter of 2015 raised 5.1%, or $1.3 million, contrast to the first quarter of 2014. The enhance in operating expenses was driven primarily by an enhance in selling, clinical, product development, and training expenses partially offset by certain acquisition transition costs comprised of in the three months ended March 31, 2014.
Loss from operations for the first quarter of 2015 was $5.1 million, contrast to $7.9 million for the first quarter of 2014. Adjusted EBITDA, a non-GAAP measure, was a loss of $2.1 million for the first quarter of 2015, contrast to a $4.7 million loss for the first quarter of 2014. Net loss per share was $0.19 for the first quarter of 2015 and $0.31 for the first quarter of 2014.
AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. The company offers Isolator Synergy ablation system and related radio frequency(RF) ablation devices, which comprise clamps that are used for ablation during open-heart procedures.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
